Core Viewpoint - The stock of Yaojie Ankang (02617.HK) experienced significant volatility, closing at 192 HKD with a decline of 53.73%, after reaching a peak of 679.5 HKD, which represented an increase of 63.73% during the trading session [1] Company Overview - Yaojie Ankang is a biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] IPO Details - Yaojie Ankang was listed on the Hong Kong Stock Exchange on June 23, 2025, with a total of 15,281,000 H-shares offered. The final number of shares for public offering in Hong Kong was 3,057,000 H-shares, while the international offering accounted for 12,224,000 H-shares [1] - The final offering price was set at 13.15 HKD per share, raising a total of 200.95 million HKD. After deducting the estimated listing fees of 39.61 million HKD, the net proceeds amounted to 161.34 million HKD [1]

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced significant volatility, dropping 45% after previously surging 63% to a peak of 679.5 HKD per share [1][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [3]. - The company has no commercialized products and reported zero revenue with a loss of 123 million HKD in the first half of the year [3]. Stock Performance - The stock price increased dramatically, with a cumulative rise of over 30 times since its IPO price of 13.15 HKD, reaching a market capitalization exceeding 120 billion HKD [3]. - The stock was recently included in the Hong Kong Stock Connect program, allowing southbound funds to invest in it [3]. Clinical Developments - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- metastatic breast cancer [3][4]. - Early clinical results indicated promising effects of Tinengotinib as a monotherapy in patients with HR+/HER2- breast cancer who have undergone multiple treatments [4]. Competitive Landscape - There are currently no other products in development with the same mechanism as Tinengotinib, although there are various competitors in related cancer treatment areas [7]. - The market for small molecule drugs is competitive, with larger biologics generally having greater potential [7]. Shareholding Structure - The founder, Wu Yongqian, holds a 32.98% stake in the company, contributing to a limited market float with only 15.281 million shares available for trading out of a total of 397 million shares [7]. - The stock exhibited a trading volatility of 131.09% with a low turnover rate of 4.74% as of September 12 [7]. Company History -药捷安康 has faced challenges in its journey to listing, having attempted to go public on three occasions in 2021, 2022, and 2024 [8]. - The company has a pipeline of six clinical-stage candidates and one preclinical candidate [8].

Group 1 - The stock price of药捷安康 (02617.HK) experienced significant volatility on September 16, with an intraday increase of over 60% followed by a decline of 53.73%, closing at 192 HKD per share and a total market capitalization of 762 billion HKD [1] - From September 11 to 15, the stock saw a cumulative increase of 361.11%, with a notable rise of 115.58% on September 15 [1] -药捷安康 is a biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] Group 2 - The company has not yet achieved commercialization, with projected losses of 343 million CNY and 275 million CNY for the years 2023 and 2024, respectively [2] - In the first half of the year, the company reported zero revenue and a loss of 123 million CNY [2] - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval for a Phase II trial for a specific type of breast cancer [1]

Core Viewpoint - The stock price of药捷安康 (02617.HK) has surged dramatically, reaching a market capitalization of over 240 billion HKD within three months of its IPO, despite the company not having any commercialized products and reporting a loss of 123 million HKD in the first half of the year [1][7]. Market Performance - As of September 16, the market capitalization of药捷安康 reached 249.3 billion HKD, surpassing established innovative pharmaceutical companies and approaching the market leader百济神州's valuation of 300 billion HKD [2]. - The stock price increased by nearly 600% over five trading days, with a peak price of 679.5 HKD on September 16 [1][6]. Investor Dynamics - The surge in stock price is attributed to significant inflows from southbound funds, which purchased over 300 million HKD worth of shares in two days [3]. - Key investors, including康方生物 and药石科技, have seen their investments yield over 50 times returns, with康方生物's shares valued at 517 million HKD compared to an initial investment of 10 million HKD [5][6]. Clinical Development - The stock's rise was triggered by the announcement of the clinical trial approval for its core product,替恩戈替尼, which targets multiple cancer pathways [3]. - As of June 30,替恩戈替尼 was involved in nine clinical trials globally, indicating a robust pipeline despite the company's current lack of revenue [3][7]. Financial Status - The company reported a net loss of 123 million HKD in the first half of the year, with research and development expenses of 98.43 million HKD and management expenses of 27.47 million HKD [7]. - As of June 30, the company held cash and cash equivalents of 449 million HKD, with total equity of 582 million HKD [7].

智通财经APP获悉，药捷安康-B(02617)尾盘跌幅进一步扩大，低见165港元，较日内高点已跌超75%， 总市值由日内最高约2700亿港元跌至不足700亿港元。截至发稿，跌60.12%，报165.5港元，全天成交额 43.45亿港元，振幅达123.98%。 消息面上，药捷安康今日午间发布称公告，公司交易价格及成交量近期出现异常变动。董事会确认，概 不知悉导致股份出现该等股价及成交量异常变动之任何原因；或任何须予公布以避免股份出现虚假市场 之资料；或根据上市规则须予披露之任何内幕消息。董事会亦确认，本集团之业务营运维持正常，且本 集团之业务营运及财务状况并无重大变动。本公司股东及潜在投资者于买卖本公司证券时务请审慎行 事。 ...

今年，港股市场最强妖股问世。 3个月50倍、市值一度猛超2500亿港元、营收为0、上半年亏损超1亿…… 无论哪个数据拉出来，6月才刚刚上市的药捷安康创下的"战绩"都能让人虎躯一震。 短短3个月，这只创新药"超级黑马"上演的狂飙大戏，缔造了资本市场惊天暴涨神话，也成为了今年港 股医药最强"鬼故事"。 在持续的蒙眼狂奔过后，今天药捷安康突然极限坠落，资本上演大逃杀正： 早上最高飙涨超60%，下午火速暴跌近50%，全天振幅超110%。 危险的狂欢 这场危险狂欢的背后，到底有多夸张？ 最近5个交易日，药捷安康一度累涨超800%。 继昨日暴涨逾115%后，周二药捷安康-B早盘继续疯狂，盘中一度涨63%，创上市新高。 不过午后，该股却突然直线高位跳水。 此前，药捷安康已实现4连升，市值最高逼近2700亿港元，超过了康方生物、信达生物。 一轮疯狂暴涨后，市场甚至已经大胆预期，未来它将超过百济神州、恒瑞医药，成为新一代医药龙头。 不过，今天午后高台跳水后，药捷安康市值已经挥发了近2000亿港元，目前市值不足千亿港元。 | | THE RIT HIT INC INC. HC PAC PAC INC 30 30 10 100 1 ...

然而与这场资本狂欢形成鲜明对比的是，公司同日公告明确表示："概不知悉股价异动原因，业务营运及财务状况无重大变动"。 更值得关注的是，这家尚无任何商业化产品、上半年亏损1.23亿元的企业，其背后基石投资者康方生物（09926.HK）与药石科技 （300725.SZ）等所持股份将于12月23日解禁，目前浮盈已超50倍。 药石科技告诉以投资者身份致电的财联社记者，"公司与药捷安康是财务投资者关系，公司还与药捷安康存在业务往来，有一些药物研发方 面协作。" 9月16日，港股市场创新药板块再现疯狂一幕。药捷安康（02617.HK）盘中市值超过2400亿港元。这只6月23日才登陆港交所的生物医药 新股，在短短三个月内股价较13.15港元的发行价飙升50倍，近5个交易日累计涨幅更是接近600%。 逼近创新药一哥百济神州港股市值 药捷安康的股价演绎堪称港股市场的"现象级"行情。继9月15日以115.58%的惊人涨幅收报415港元后，该股今日延续疯狂走势，截至今日 盘中涨幅收窄至49.40%，报620港元，总市值达2461亿港元。 财联社记者注意到，截至盘中，药捷安康市值达到2493亿港元，这将一众老牌创新药企远远甩在身后—— ...

（文章来源：每日经济新闻） 每经AI快讯，9月16日，药捷安康-B跌超40%，早盘一度涨超60%，全天振幅超100%，股价跌破250港 元，总市值回落至1000亿港元下方，成交额近35亿港元。 ...

Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced significant volatility, dropping 45% after a previous surge of 63%, highlighting the speculative nature of its recent trading activity [2][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases. The company currently has no commercialized products and reported zero revenue with a loss of 123 million yuan in the first half of the year [2]. Recent Developments - The company was recently added to the Hong Kong Stock Connect list, allowing southbound funds to purchase its shares [3]. - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- metastatic breast cancer [3]. Competitive Landscape - Industry experts noted that there are currently no other products in development with the same mechanism as Tinengotinib, although there are various competitors in related cancer treatment areas [6]. - Despite the innovative mechanism of Tinengotinib, the stock price increase has been described as excessive, and the potential of large molecule drugs is generally considered greater than that of small molecules [6]. Market Dynamics - The founder of药捷安康, Wu Yongqian, holds a 32.98% stake in the company, contributing to a limited market float. Out of a total of 397 million shares, only 15.28 million are available for trading in the secondary market [6]. - The stock exhibited a trading volatility of 131.09% with a turnover rate of only 4.74%, indicating a tight liquidity situation [6]. Historical Context -药捷安康 has faced a challenging path to listing, having attempted to go public on three occasions in 2021, 2022, and 2024 [7]. - The company has a pipeline of six clinical-stage candidates and one preclinical candidate [7].

北京商报讯（记者 丁宁）9月16日，药捷安康（02617.HK）盘中股价跳水翻绿后，盘中跌幅继续扩大， 一度跌逾50%，截至北京商报记者发稿，药捷安康报226港元/股，跌幅为45.54%。 ...